Generic Medicine Info
Indications and Dosage
Adult: Initially, 25 mg bid, adjusted in increments of 25 mg or 50 mg at 2-wk intervals to a max of 200 mg daily in 2 or 3 divided doses.
Elderly: Reduce dose or dosing frequency.

Benign prostatic hyperplasia
Adult: Initially, 20 mg bid, increased if necessary by 20 mg at 2-wk intervals, to a max of 100 mg daily in divided doses.
Elderly: Reduce dose or dosing frequency.
Established heart failure; history of micturition syncope and history of postural hypotension when used for benign prostatic hyperplasia. Concomitant admin w/ MAOIs.
Special Precautions
Patient w/ history of depression, epilepsy or Parkinson's disease. Patient undergoing cataract surgery. Hepatic or renal impairment. Elderly. Pregnancy and lactation.
Adverse Reactions
Sedation, dizziness, dry mouth, nasal congestion, headache, fatigue, depression, wt gain, failure of ejaculation, orthostatic hypotension, syncope, extrapyramidal disturbances.
Patient Counseling Information
This drug may cause drowsiness, if affected, do not drive or operate machinery.
Symptoms: Deep sedation leading to coma, hypotension and fits. Management: Recent ingestion would require gastric lavage or a dose of ipecacuanha. Assist and monitor ventilation. Maintain circulatory support and control of hypotension. Monitor temp and carry out rewarming to avoid convulsions. If convulsions occur, may admin diazepam.
Drug Interactions
Enhanced hypotensive effect w/ anaesth, antidepressants, other antihypertensives, β-blockers, Ca-channel blockers, diuretics esp thiazides.
Potentially Fatal: Enhanced hypotensive action of MAOIs.
Food Interaction
Increased rate and extent of absorption w/ alcohol, avoid use.
Description: Indoramin is an α-adrenoceptor blocking agent, which acts selectively and competitively on post-synaptic α1-adrenoceptors, causing a decrease in peripheral resistance. It also relaxes hyperplastic muscle in the prostate.
Absorption: Readily absorbed from the GI tract. Time to peak plasma concentration: 1-2 hr.
Distribution: Plasma protein binding: Approx 90%.
Metabolism: Extensively metabolised; undergoes first-pass metabolism.
Excretion: Via urine (35%) and faeces (46%), mainly as metabolites. Half-life: Approx 5 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Indoramin, CID=33625, (accessed on Jan. 21, 2020)

Store at or below 25°C.
MIMS Class
Other Antihypertensives
ATC Classification
C02CA02 - indoramin ; Belongs to the class of alpha-adrenoreceptor antagonists, peripherally-acting antiadrenergic agents. Used in the treatment of hypertension.
Buckingham R (ed). Indoramin Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 16/03/2016.

Joint Formulary Committee. Indoramin. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 16/03/2016.

Disclaimer: This information is independently developed by MIMS based on Indoramin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in